CG Oncology reported phase 3 results showing its oncolytic-virus immunotherapy cretostimogene reduced the risk of tumor recurrence by 68% over 17 months in certain patients with non-muscle invasive bladder cancer following surgery. The study enrolled patients considered intermediate-risk with high-grade Ta NMIBC, and the company said no new safety signals were seen.

The result matters beyond a single trial readout because it broadens the clinical case for cretostimogene beyond the high-risk setting where CG had already reported late-stage activity. CG now plans to expand its initial FDA submission so it covers patients with bladder cancer containing carcinoma in situ with or without papillary tumors and also patients with high-grade papillary-only disease, which the company said represents the full range of Bacillus Calmette-Guérin-unresponsive disease.

The Data

The 367-patient study, called PIVOT-006, tested cretostimogene in the adjuvant setting after surgery to remove the tumor. Cretostimogene is injected directly into the bladder to target cancer cells.

According to the company, the recurrence-free survival benefit was seen in patients with intermediate-risk high-grade Ta NMIBC, and Vijay Kasturi, M.D., CG’s chief medical officer, said the improvement was observed across both high-grade and low-grade patients. The source did not provide a separate numerical breakout for those subgroups.

Regulatory Path

CG said it plans to complete the expanded FDA submission by the end of 2027’s first quarter. In intermediate high-grade Ta NMIBC, it aims to submit a second application with the FDA in next year's second quarter.

The signal for investors and competitors is that CG is not treating this dataset as support for a limited niche launch. With one late-stage program in high-risk NMIBC and another in intermediate-risk disease, the company is building a case that cretostimogene could compete across a wider share of the NMIBC market if regulators agree with the broader filing strategy.

CG has been public since a $380 million outing in 2024. With another late-stage study in hand and clearer FDA plans, the company has added evidence that its post-IPO story depends on label breadth as much as on a single approval outcome.